Block Deal: Hema CIPEF likely to sell around 1% stake in Mankind Pharma
Capital Group held a 2.22% stake in the company as on March 31, 2024. In December last year, Capital Group divested a 3.14% stake in Mankind Pharma.
Mumbai: Hema CIPEF (I), an affiliate of the US-based , is likely to sell a 0.9% stake in on Wednesday through block deals, according to the term sheet issued by bankers . Hema CIPEF is offering to sell 37 lakh shares at a floor price of Rs 2,061 per share, which is a 2% discount to Tuesday's closing price of Rs 2,102.50 on the NSE. The deal at the floor price is valued at Rs 763 crore.Capital Group held a 2.22% stake in the company as on March 31, 2024. In December last year, Capital Group divested a 3.14% stake in Mankind Pharma.
Mankind Pharma launched its maiden public offer in April of last year. The Rs 4,326-crore initial share sale of Mankind Pharma was subscribed 15.32 times. The IPO was listed on May 5 of last year at a premium of 31% and has rallied 48% since then.
Source: Stocks-Markets-Economic Times
